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Ovarian clear cell adenocarcinoma (OCCA) has been recognized
as a distinct histological entity in the World Health Organization
(WHO) classification of ovarian tumours since 1973 (Serov et al,
1973). OCCA constitutes 8% to 10% of all ovarian epithelial
malignancies (Kennedy et al, 1989) and has a worse prognosis
than other types of ovarian cancer (Jenison et al, 1989; Goff et al,
1996). Although the outcome of patients with early-stage disease
is substantially better than that of their counterparts with
advanced-stage disease, a significant proportion of women (20%
to 50%) with stage I OCCA have recurrence and die of their malig-
nancy (O’Brien et al, 1993). It would be desirable to have accurate
methods to identify patients with early stage OCCA who are at
high risk for tumour progression. Histological grade has been
shown to be useful as an initial prognostic determinant in some
studies of epithelial cancer of the ovary (Haapasalo et al, 1990,
1991; Kennedy et al, 1993), but the histological grading of OCCA
is still controversial and complicated by the multiplicity of histo-
logical patterns presented in the same tumour. Some previous
works have focused on the prognostic value of nuclear grading
systems, such as the Fuhrman grading system (Fuhrman et al,
1982) for renal cell carcinoma and Christopherson’s criteria
(Christopherson et al, 1982) for endometrial clear cell carcinoma.
Unfortunately, neither of these grading systems has shown predic-
tive value for survival (Montag et al, 1989).
During the last decade, various investigators have demonstrated
the usefulness of nuclear morphometry as a predictor of the
clinical behaviour for a wide variety of neoplasms (Sharkey et al,
1983; Colombel et al, 1995; Fukuzawa et al, 1995; Nativ et al,
1995) including ovarian carcinoma (Miller et al, 1991). However,
the question remains unresolved as to whether nuclear morphome-
tric parameters may reflect the biological virulence of a particular
tumour in the individual. In this study, we measured nuclear vari-
ables in 40 patients with OCCA locally restricted to the ovary and
studied the relations of these variables to clinical prognostic
factors and outcome.
MATERIAL AND METHODS
Patients
Between January 1988 and March 1996, a total of 168 consecutive
patients with TNM stage T1 (defined as intra-abdominal disease
confined to one or both ovaries) invasive epithelial ovarian cancer
were treated at the Department of Obstetrics & Gynecology of the
Jikei University School of Medicine Hospital, Tokyo, Japan.
Among them, 40 (23.8%) patients were found to have pure ovarian
clear cell adenocarcinoma. Patients were staged by the TNM
staging system and the local diseases were substaged according to
the 1986 revised staging system of the International Federation 
of Gynecology & Obstetrics. All patients underwent a surgical
staging procedure consisting of a total abdominal hysterectomy
and bilateral salpingo-oophorectomy in addition to an infracolic
omentectomy, peritoneal cytological washings, and biopsies of all
places in the abdominal cavity at risk for tumour metastasis.
Twenty-one patients underwent pelvic and paraoartic lymph-
adenectomy. The selection of patients for lymphadenectomy was
influenced by surgical findings, the medical condition, anaesthetic
considerations and the skill of the surgeon. All patients received
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adjuvant therapy consisting of six courses of a combination of
cisplatin, adriamycin and cyclophosphamide (CAP). Follow-up
data were obtained by reviewing hospital records. Survival was
considered the primary end-point and survival time was measured
from the date of diagnosis to the date of death or last contact. 
The deaths recorded in the study all were related directly to 
carcinoma.
Morphometric analysis
The samples were fixed in 10% buffered neutral formalin and
embedded in paraffin. Sections of 5-mm thickness were cut and
stained with haematoxylin and eosin. One experienced gynaeco-
logical pathologist (AS) reviewed all tumour slides and selected
two identical slides for each case. The slides were coded by
consecutive numbers, and all histological and morphometric
analyses were performed without knowledge of patient identity
and outcome.
Five photographs were taken with high-resolution black-and-
white film at ´ 1150 magnification with an Olympus Microscope.
The cell-field images were captured by the operator, who moved
the microscopic fields randomly across the specimen. Areas with
inflammation and necrosis (if present) were carefully avoided.
Each photograph included 30 to 60 cells. All clear-cell adenocarci-
noma nuclei within the chosen field that could be focused sharply
were traced. The images were processed with an IBM-compatible
personal computer, an imaging screen, and image measurement
software (Image Command 5098, version 2.43). From each
tumour, the characteristics of about 160 to 350 nuclei were
measured. Fifty of these nuclei were randomly selected with the
use of a computer-generated list of random numbers for further
analysis. For each nucleus, four variables were measured directly:
nuclear area (NA); nuclear longer diameter (NLD); nuclear
perimeter (NP); and the nuclear roundness factor (NRF). The NRF
was defined as the degree to which the nucleus in cross-section
approximated a perfect circle. If the nucleus was a perfect circle in
cross-section then it was assigned a roundness factor of 1.00. As
the nuclear shape deviates from that of a perfect circle, values of
NRF depart from 1.00. NRF was computed from the following
formula: nuclear roundness factor = M.NP/I.NP, where M.NP is
the measured perimeter, and I.NP is the perimeter of an imaginary
perfect circle with an area equivalent to the measured nuclear area.
Statistical analysis
The distribution of each morphometric variable was examined as a
histogram for each patient according to survival and disease recur-
rence status. Because of a positive skew in the data for patients
who died, the median was used to describe each patient’s distribu-
tion. Nuclear irregularity was defined as present if the patient
median NRF was greater than or equal to 1.04, which was the 75th
percentile of all patient median NRF values. A giant nuclear cell
(GNC) was defined as any cell with an NLD greater than or equal
to twice the median NLD for a given patient. Between-patient
differences in nuclear morphometry were summarized using the
median and interquartile range (IQR) of each patient’s median
value. Associations between clinical or morphometric factors and
death or disease recurrence were measured by sensitivity, speci-
ficity and the odds ratio (OR). Conditional maximum likelihood
was used to estimate ORs and exact mid-P confidence intervals
(CIs) (Williams, 1988). The Kaplan–Meier method was used to
estimate survival curves and the log-rank statistic to test for a
difference between curves. PEPI version 2.05 was used to
compute exact mid-P values and confidence intervals (Gahlinger
and Abramson, 1995) for sensitivity, specificity and the odd ratio.
Klotz’s linked list method was used to compute exact P-values for
the Wilcoxon rank sum test (Klotz et al, in press)
RESULTS
Patient characteristics are shown in Table 1. The median age of the
patients was 50 years (IQR 43 to 58 years). Eighteen patients had
stage T1a and 22 stage T1c cancer. Two of the 21 patients who
underwent lymphadenectomy were found to have pelvic lymph
node involvement, and one patient had both pelvic and para-arotic
lymph node metastasis. The median follow-up of the six patients
who died was 788 days (IQR 644 to 1205 days) and the median
follow-up of the remaining patients was 1484 days (IQR 1150 to
2012 days). Eight patients relapsed during the follow-up.
The distribution of NLD for a patient who died 862 days after
primary surgery is shown in Figure 1A, and for a patient who was
alive at the end of follow-up in Figure 1B. Distributional patterns
similar to these figures were seen in many patients and values of
NLD were spread over a greater range among patients who died
than among those who were alive at the end of follow-up.
However, this finding was mainly due to the presence of a small
number of very large nuclear cells. Similar distributional patterns
were observed in patients with and without disease recurrence and
with respect to other variables of cell morphometry (data not
shown).
The median and interquartile range of each patient’s individual
median values were reported according to survival and disease
recurrence for each morphometric variable in Table 2. Summary
median values were higher among patients who died than among
survivors for all of nuclear morphometric variables. Median differ-
ences (died vs alive) were statistically significant for NLD (10.5 vs
Table 1 Characteristics of 40 patients with stage T1 ovarian clear cell
carcinoma
Characteristic No. of patients (%)
Died 6 (15)
Disease recurrence 8 (20)
Age > 50 years old 20 (50)
Substage
T1a 18 (45)
T1c 22 (55)
Lymphadenectomy 21 (52)
Metastasis 3/21 (14)
No metastasis 18/21 (86)
Giant nuclear cella 9 (22)
Nuclear irregularityb 10 (25)
Giant nuclear cell or nuclear irregularity 15 (38)
aCell with a nuclear longer diameter (NLD) greater than or equal to twice the
median NLD. bPatient median nuclear roundness factor (NRF) greater than or
equal to 1.040.1738 CQ Liu et al
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9.0 mm,  P = 0.03), NP (30.2 vs 26.7 mm,  P = 0.05) and NRF
(1.046 vs 1.028, P < 0.01), but not for NA (65.6 vs 52.6 mm2,
P = 0.07). A similar pattern was observed among patients with and
without disease recurrence, although the differences were smaller,
and statistical significance was found only for NLD (10.1 to 9.0
mm, P = 0.05) and NRF (1.044 vs 1.024, P < 0.01). Of the patients
who underwent lymphadenectomy, median values were higher
among those with lymph node metastasis than those without
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Figure 1 (A) Distribution of nuclear longer diameter from one patient with OCCA who died 862 days after primary surgery. (B) Distribution of nuclear longer
diameter from one patient with OCCA who showed no evidence of recurrence 2124 days after the primary surgery
Table 2 Summary of nuclear morphometry measures according to survival and disease recurrence status
Measure Case status
Died Alive Recurrence No recurrence
(n = 6) (n = 34) (n = 8) (n = 32)
Nuclear area (mm2)
Median 65.6* 52.6 64.5* 52.6
Interquartile range 63.8–69.9 47.3–63.9 55.3–67.9 47.2–66.5
Nuclear longer diameter (mm)
Median 10.5** 9.0 10.1** 9.0
Interquartile range 10.0–10.8 8.4–10.2 9.5–10.8 8.4–10.3
Nuclear perimeter (mm)
Median 30.2** 26.7 29.6 26.7
Interquartile range 29.6–31.6 25.0–30.0 27.4–31.1 25.0–30.1
Nuclear roundness factor
Median 1.046*** 1.028 1.044*** 1.028
Interquartile range 1.037–1.059 1.024–1.038 1.034–1.054 1.024–1.037
P-value for comparison with the adjacent column by Wilcoxon rank sum test, *, P > 0.05, **, P ≤ 0.05, ***, P ≤ 0.005.Nuclear morphometry in T1 ovarian clear cell adenocarcinoma 1739
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metastasis for both NLD (10.3 vs 91 mm, P = 0.03) and NRF
(1.044 vs 1.030, P = 0.09).
The association between clinical or morphometric factors and
survival or disease recurrence is reported in Table 3. The presence
of one or more GNCs was positively associated with death
(OR = 10.6, P = 0.02) and tended to be associated with disease
recurrence (OR = 5.1, P = 0.07). Nuclear irregularity was posi-
tively associated with both death (OR = 8.6, P = 0.02) and disease
recurrence (OR = 8.3, P = 0.02). The presence of GNC or nuclear
irregularity in combination was associated with both death
(OR = 11.2, P = 0.02) and disease recurrence (OR = 7.2, P = 0.02).
The sensitivity and specificity of the presence of GNC or nuclear
irregularity were 83% (95% CI: 41, 99) and 71% (95% CI: 54, 84)
for the prediction of death, and 75% (95% CI: 56, 89) and 71%
(95% CI: 54, 84) for the prediction of recurrence, respectively.
When the sample size was sufficient, ORs for all associations
involving either GNC or irregularity were adjusted separately for
age and stage. The adjusted results were similar to the crude
results and are not reported. Patient age and the substage did not
show any association with death or disease recurrence.
Survival of patients without a GNC was better than that of
patients with a GNC (c2 = 8.0, P < 0.01), as shown in Figure 3.
After 19 months the survival rate was 100% in patients without a
GNC (first death after 858 days) and 89% for patients with one or
more GNCs (first death after 567 days). The 2-year survival rates
were 100% and 63%, respectively. Among patients without a
Table 3 Bivariable association between clinical or nuclear morphometry factors and outcomea
Death Disease recurrence
Factor OR (CI) P-value OR (CI) P-value
Age > 50 years old 2.21 (0.34, 19) 0.422 1.86 (0.37, 11) 0.465
Stage T1c 0.79 (0.12, 5.2) 0.804 0.78 (0.15, 4.0) 0.765
Giant nuclear cell 10.6 (1.5, 102) 0.017 5.1 (0.89, 31) 0.067
Nuclear irregularity 8.6 (1.3, 81) 0.016 8.3 (1.5, 55) 0.016
Giant nuclear cell or
nuclear irregularity 11.2 (1.4, 296) 0.020 7.2 (1.5, 55) 0.024
aExact mid-P values and confidence intervals were computed.
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Figure 2 Survival of patients with or without GNC (giant nuclear cell) groups: –n n –– no giant nuclear cell; –l l –– presence of one or more giant nuclear cellGNC, the numbers at risk of death at 12, 18 and 24 months were
31, 31 and 28 respectively, as compared with 9, 9 and 5 among
patients with one or more GNCs.
DISCUSSION
The anatomical extent of tumour at diagnosis has been the most
important parameter for determining the outcome of patients with
epithelial ovarian cancer. Approximately 40% of all patients
present with FIGO stage I. The 5-year survival is related to FIGO
stage ranging from 82% for FIGO stage Ia to 68% for stage Ic.
Several studies have shown that histological grade was the most
important predictor of outcome in stage I disease, and for patients
with FIGO stage Ia, Ib and well- or moderately differentiated
tumours adjuvant therapy after surgery is unnecessary (Dembo et
al, 1990; Finn et al, 1992). However, the situation is quite different
for OCCA. Comparison of survival for patients with OCCA and
papillary serous histology have shown that OCCA is associated
with a poorer outcome. In a study by Jenison and colleagues, the
estimated 5-year survival for patients with stage I OCCA were
50% compared with 87% for papillary serous carcinoma (Jenison
et al, 1989). The same tendency was also found for patients with
stage III patients, with a median survival of 12 months compared
with 22 months for papillary serous carcinoma (Goff et al, 1996).
Moreover, there is no clearly defined, generally accepted and
widely used grading system for OCCA. The GOG Pathology
Manual published in 1994 did not include a grading system for
OCCA (Benda and Zaino, 1994). Our preliminary investigation
found that Fuhrman’s grading system for renal carcinoma did not
stratify effectively the tumours among the four grades, with only
7.5% (3/40) classified as grade 1 or grade 2 (unpublished data).
This is in accordance with the data of Kennedy and colleagues
(Kennedy et al, 1993). Histoquantitative techniques have gener-
ated considerable interest because of their potential to improve
subjective grading. Nuclear morphometry attempts to quantify
phenotypical heterogeneity in terms of shape alterations, while
flow cytometry may identify chromosomal aberrations in terms of
changes in the DNA content. Compared with flow cytometry,
nuclear morphometry analysis is a simple, objective and inexpen-
sive method for identifying malignant features in tumour cells.
Morphometry analysis is performed on routine H&E sections and
noncancer nuclei can be avoided. The accuracy of nuclear
morphometry analysis may be superior to flow cytometry in the
detection of minimal change and rare events (Miller et al, 1991).
An important finding of this study was that the presence of
GNC or nuclear irregularity was positively associated with the
tumour progress of TNM stage T1 OCCA. For ovarian cancer, the
percentage of hyperploid cells (with nuclear DNA content ³5C)
has been found to be significantly higher in grades 2 and 3 than in
grade 1 tumours, i.e. in rapidly progressive tumours compared
with less aggressive malignancies (Miller et al, 1991). It may iden-
tify high-risk patients with ovarian cancer (Wagner et al, 1994).
Rodenburg et al (1988) labelled hyperploid cells as ‘marker cells’
for malignant changes, such as increased genetic instability and
impaired growth regulation. Nuclear size has been found to be
associated with the DNA content of the cells (Baak et al, 1988)
and it is reasonable to assume that the GNCs identified by
morphometry in this study are consistent with these observations.
While many different nuclear descriptors have been used to
summarize the morphology of the nucleus, nuclear size is the most
widely used parameter. Giant nuclear cells can be readily identi-
fied and appear to be more reproducible.
Nuclear irregularity has long been used by pathologists to be an
indicator of malignant potantial for various types of tumour.
However, such assessment is subjective and poorly reproducible. It
was not until 1984 that Diamond et al (1984) first proposed the
concept of the nuclear roundness factor as a prognostic indicator for
patients with stage B1 and B2 prostatic carcinoma after radical
prostatectomy. Partin and colleagues measured 16 different descrip-
tors and they found that nuclear roundness factor was the most
useful shape descriptor for the prediction of disease-free interval for
patients with stage A2 prostate cancer (Partin et al, 1989). In our
present work, nuclear irregularity was positively associated with
both death and disease recurrence. This result is in agreement with
the studies of Pound et al (1993) on renal cell carcinoma and of
Borland et al (1993) on deeply invasive bladder carcinoma.
Pelvic lymph node metastasis has been reported to occur in 8%
to 15% and para-aortic lymph node metastasis in 5% to 24% of
patients with intra-abdominal stage I ovarian cancer (Petru et al,
1994). FIGO has recommended evaluating retroperitoneal lymph
nodes in the staging of ovarian cancer patients. It is still unclear
whether patients who receive lymphadenectomy for early-stage
ovarian cancer benefit from this procedure (Finn et al, 1992; Petru
et al, 1994). The ability to identify patients at high risk for
lymphatic involvement would allow us to limit retroperitoneal
lymphadenectomy selectively to a subset of patients whose
tumours show a high metastatic potential. There were three patients
in this study who had pelvic or para-aortic lymph node involvement
or both. The result of the nuclear morphometric analysis of these
three tumours was consistent with the hypothesis that nuclear size
and shape are correlated with the tendency to lymphatic involve-
ment even when the disease is locally confined to the ovary.
Although a large study is required to quantify precisely the strength
of association between NLD and metastasis potential, our results
suggest an hypothesis for further investigation.
The present treatment for ovarian cancer is by no means ideal.
One way to obtain a more rational basis for the treatment policy
may be better biological characterization of the tumour. The use of
several prognostic variables may allow us to tailor treatment to
individual patients with OCCA and thereby provide maximal 
therapeutic benefit with minimal risk. Nuclear morphometry, 
especially the quantitative, objective measurement of nuclear
heterogeneity and nuclear pleomorphism seems to be a step in that
direction.
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